A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision filed late Wednesday, Judge Mark Pittman of the Northern District of Texas declined to issue an injunction to stop the FDA from declaring there was no longer a shortage of the medicines' active ingredient, tirzepatide.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
